RaySearch Laboratories Management

Management criteria checks 3/4

RaySearch Laboratories' CEO is Johan Lof, appointed in Jan 2000, has a tenure of 24.33 years. total yearly compensation is SEK9.76M, comprised of 66.2% salary and 33.8% bonuses, including company stock and options. directly owns 16.51% of the company’s shares, worth SEK800.53M. The average tenure of the management team and the board of directors is 5.6 years and 20.7 years respectively.

Key information

Johan Lof

Chief executive officer

kr9.8m

Total compensation

CEO salary percentage	66.2%
CEO tenure	24.3yrs
CEO ownership	16.5%
Management average tenure	5.6yrs
Board average tenure	20.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Johan Lof's remuneration changed compared to RaySearch Laboratories's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	kr101m
Dec 31 2023	kr10m	kr6m	kr82m
Sep 30 2023	n/a	n/a	kr64m
Jun 30 2023	n/a	n/a	kr53m
Mar 31 2023	n/a	n/a	kr22m
Dec 31 2022	kr7m	kr6m	kr24m
Sep 30 2022	n/a	n/a	-kr6m
Jun 30 2022	n/a	n/a	-kr38m
Mar 31 2022	n/a	n/a	-kr35m
Dec 31 2021	kr7m	kr6m	-kr47m
Sep 30 2021	n/a	n/a	-kr46m
Jun 30 2021	n/a	n/a	-kr50m
Mar 31 2021	n/a	n/a	-kr42m
Dec 31 2020	kr7m	kr6m	-kr9m
Sep 30 2020	n/a	n/a	kr24m
Jun 30 2020	n/a	n/a	kr43m
Mar 31 2020	n/a	n/a	kr74m
Dec 31 2019	kr8m	kr6m	kr50m
Sep 30 2019	n/a	n/a	kr64m
Jun 30 2019	n/a	n/a	kr85m
Mar 31 2019	n/a	n/a	kr84m
Dec 31 2018	kr8m	kr5m	kr79m
Sep 30 2018	n/a	n/a	kr118m
Jun 30 2018	n/a	n/a	kr104m
Mar 31 2018	n/a	n/a	kr103m
Dec 31 2017	kr9m	kr5m	kr118m

Compensation vs Market: Johan's total compensation ($USD915.13K) is about average for companies of similar size in the UK market ($USD978.43K).

Compensation vs Earnings: Johan's compensation has increased by more than 20% in the past year.

CEO

Johan Lof (54 yo)

24.3yrs

Tenure

kr9,758,000

Compensation

Dr. Johan Lof has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Lof serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Lof has been a Di...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Johan Lof	Founder	24.3yrs	kr9.76m	16.51% SEK 800.5m
Bjorn Hardemark	Deputy Chief Executive Officer	8.7yrs	kr3.54m	0.052% SEK 2.5m
Annika Henriksson	Deputy Chief Financial Officer	less than a year	no data	no data
Kjell Eriksson	Head of Research & Chief Science Officer	8.7yrs	no data	0.070% SEK 3.4m
Petra Jansson	General Counsel	6.8yrs	no data	no data
Peter Kemlin	Director of Sales & Marketing	no data	no data	0.0041% SEK 197.8k
Tove Alteborg	Global Human Resource Manager	less than a year	no data	no data
Fredrik Lofman	Head of Machine Learning	4.3yrs	no data	0.0041% SEK 197.8k
Marc Mlyn	President & CEO of RaySearch Americas	2.3yrs	no data	no data

5.6yrs

Average Tenure

49.5yo

Average Age

Experienced Management: 0GRZ's management team is seasoned and experienced (5.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Johan Lof	Founder	24.3yrs	kr9.76m	16.51% SEK 800.5m
Hans Wigzell	Independent Chairman of Board	20yrs	kr840.00k	no data
Carl Bergendal	Independent Director	24.3yrs	kr225.00k	3.39% SEK 164.2m
Radhe Mohan	Member of Scientific Advisory Board	21.3yrs	no data	no data
Anders Forsgren	Member of Scientific Advisory Board	no data	no data	no data
Anders Brahme	Member of Scientific Advisory Board	no data	no data	3.79% SEK 183.8m
David Jaffray	Member of Scientific Advisory Board	no data	no data	no data
Britta Wallgren	Independent Director	6yrs	kr300.00k	0.020% SEK 989.9k
Gunther Marder	Independent Director	1.5yrs	kr300.00k	0.20% SEK 9.9m

20.7yrs

Average Tenure

69yo

Average Age

Experienced Board: 0GRZ's board of directors are seasoned and experienced ( 20.7 years average tenure).

RaySearch Laboratories Management

Management criteria checks 3/4

Key information

Recent management updates

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold kr40m worth of stock

Director recently bought kr88k worth of stock

Founder recently sold kr1.1m worth of stock

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Recent updates

Now 21% undervalued

Raysearch Laboratories AB (Publ) Apprves Ordinary Dividend for the Year 2023

First quarter 2024 earnings released: EPS: kr1.07 (vs kr0.51 in 1Q 2023)

Upcoming dividend of kr2.00 per share

Raysearch to Present the Latest Advances in Raystation, Raycare and Rayintelligence At Estro 2024

Investor sentiment improves as stock rises 18%

Full year 2023 earnings released: EPS: kr2.38 (vs kr0.69 in FY 2022)

New major risk - Revenue and earnings growth

RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

RaySearch Laboratories AB (publ) Releases Raystation 2024A

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023

RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024

Second quarter 2023 earnings released

RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023

RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System

RaySearch Laboratories AB (publ) Releases Raystation 2023B

Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold kr40m worth of stock

New minor risk - Shareholder dilution

RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023

First quarter 2023 earnings released

Director recently bought kr88k worth of stock

Founder recently sold kr1.1m worth of stock

Full year 2022 earnings released: EPS: kr0.69 (vs kr1.38 loss in FY 2021)

RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Third quarter 2022 earnings released

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released

Now 29% undervalued after recent price drop

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

RaySearch Laboratories AB (publ) Launches RayStation 12A

RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022

RaySearch Laboratories AB (publ) Releases Latest Version of RayCare

Founder recently sold kr20m worth of stock

First quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022

Insufficient new directors

RaySearch Laboratories AB (publ) Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Founder recently sold kr5.6m worth of stock

RaySearch AB (publ) Provides Cancer Clinics with User Configurable Workflows for Radiation Therapy

RayStation 11B Brings New Features for Adaptive Workflows, Brachytherapy, and Radiation Therapy with Ions

Third quarter 2021 earnings released

RaySearch Laboratories AB (publ) to Showcase Latest Innovations, RayIntelligence and RayCare at ESTRO 2021

Second quarter 2021 earnings released

Insufficient new directors

RaySearch Laboratories AB (Publ) Announces RayStation 9 Granted Regulatory Clearance in China

Raysearch Announces the Release of A New Version of Raycare®, the Next-Generation Oncology Information System

Raysearch Laboratories Announces the Release of Raystation® 11A

Raysearch Laboratories AB (Publ) Provides Earnings Guidance for 2021

RaySearch Laboratories AB (publ) Announces Royal Brisbane and Women's Hospital Treats First Patients Using the Raystation® Treatment Planning System

New 90-day high: kr93.60

Full year 2020 earnings released: kr0.26 loss per share (vs kr1.47 profit in FY 2019)

Revenue misses expectations

RaySearch Laboratories AB (publ) to Report First Half, 2021 Results on Aug 25, 2021

RaySearch Laboratories AB (publ) Announces University Medical Center Maribor in Slovenia Became the 700th Customer to Select RayStation

New 90-day high: kr91.55

RaySearch Receives New Order from Centre Antoine Lacassagne for RayStation in France

RaySearch Laboratories AB (Publ) Announces the Release of the First Version of the Treatment Control System (TCS) Raycommand